Every Form 4 that PepGen Inc. (PEPG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PEPG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PEPG filings page.
PepGen Inc. reported a compensation-related transaction involving an option grant linked to RA Capital-managed entities. An option over 34,000 shares of common stock was awarded at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option will vest in full on the earlier of the first anniversary of the grant date or PepGen’s next annual stockholder meeting, subject to continued board service by Dr. Resnick. Under his arrangement with RA Capital, any net cash or stock from exercising the option will benefit RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, offsetting advisory fees, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
PepGen Inc. reported that director Lisa Wyman received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued service as a director.
PepGen Inc. reported that director Joshua Resnick received a grant of stock options covering 34,000 shares of Common Stock at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, with vesting stopping if he ceases to serve as a director unless the Board decides otherwise. Under his arrangement with RA Capital Management, L.P., Resnick holds this option for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, must turn over any net cash or stock on exercise to RA Capital, and disclaims beneficial ownership of the option and underlying shares.
PepGen Inc. director Howard Mayer received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036. This grant is compensation-related and does not represent an open-market purchase or sale of shares.
According to the vesting terms, the option vests in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting, with vesting stopping if he ceases to serve as a director unless the board decides otherwise. Following this grant, Mayer holds 34,000 options directly.
PepGen Inc. director Mitchell H. Finer received a grant of stock options covering 34,000 shares of common stock. The options carry an exercise price of $1.79 per share and expire on June 17, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, and vesting stops if he ceases to serve as a director unless the board decides otherwise. Following this grant, he holds 34,000 stock options directly, as reported in this filing.
PepGen Inc. director Habib J. Dable received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036.
The award vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to continued board service unless the board decides otherwise. Following this grant, Dable holds 34,000 options directly, and the filing shows no open-market buying or selling.
PepGen Inc. director Heidi Henson received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036.
These options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to continued service on the board unless the board determines otherwise.
PepGen Inc. director Laurie Keating reported a new compensation award on a Form 4. She received a stock option to buy 34,000 shares of PepGen common stock at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the date of the next Annual Meeting, as long as she continues serving as a director, unless the board decides otherwise. After this grant, Keating holds options covering 34,000 underlying shares from this award.
PepGen Inc. Chief Technical Officer Kasraian Kasra reported an automatic sale of 1,233 shares of Common Stock on May 21, 2026 at a weighted average price of $1.4107 per share, with individual trades ranging from $1.41 to $1.4541.
According to the disclosure, the shares were sold by the company under a mandatory sell-to-cover provision tied to vested restricted stock units, solely to satisfy minimum statutory tax withholding obligations. The filing states this sale was made under an RSU agreement treated as a binding contract consistent with the Rule 10b5-1 affirmative defense and does not represent a discretionary trade by the insider. Following the transaction, Kasraian Kasra directly holds 50,074 shares of PepGen common stock.
PepGen Inc. executive Paul Streck, EVP and Head of R&D, had 1,879 shares of common stock sold on March 4, 2026 at prices between $6.23 and $6.29. The footnote explains these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding due on vested restricted stock units, and the sale is described as non-discretionary under a Rule 10b5-1 "binding contract". After these transactions, Streck directly holds 76,226 common shares.
PepGen Inc. Chief Financial Officer Noel Donnelly had a total of 2,084 shares of common stock automatically sold on March 4, 2026 in open-market transactions at prices of $6.23 and $6.325 per share. According to the disclosure, these mandatory sell-to-cover trades were executed by the company to satisfy minimum statutory tax withholding due upon vesting and settlement of restricted stock units under a pre-existing Rule 10b5-1 compliant agreement, rather than as discretionary sales by the executive. Following these transactions, Donnelly directly holds 111,603 shares of PepGen common stock.
PepGen Inc. president and CEO James G. McArthur reported automatic sales of common stock tied to restricted stock units. On the transactions date, a total of 5,275 shares were sold at prices of $6.23 and $6.325 per share to cover minimum statutory tax withholding obligations, and he held 296,326 shares afterward. The filing states these sales were made under a mandatory sell-to-cover provision and did not represent discretionary trades.
Vittiglio Joseph reported acquisition or exercise transactions in this Form 4 filing.
PepGen Inc. reported that Chief Business & Legal Officer Joseph Vittiglio received new equity awards. He was granted stock options for 120,000 shares of PepGen common stock, which vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, subject to his continued service.
He also received 30,717 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting. These RSUs vest in equal annual installments over four years, beginning on March 1, 2027, contingent on continued service. Following the RSU grant, he directly owned 65,717 shares of common stock.
PepGen Inc. reported new equity awards for Chief Technical Officer Kasra Kasraian. On March 1, 2026, he received stock options for 135,000 shares at an exercise price of $0.00 per share and 34,557 restricted stock units, each representing one share of common stock upon vesting.
The RSUs vest in four equal annual installments starting on March 1, 2027, contingent on continued service. The option vests 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, also conditioned on continued service.
PepGen Inc. executive Paul Streck, EVP and Head of R&D, reported awards of equity-based compensation. He received stock options covering 196,500 shares at an exercise price of $0.00 per share and 50,300 shares of common stock in the form of restricted stock units. The RSUs vest in equal annual installments over four years starting on March 1, 2027, while the option vests 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, in each case conditioned on continued service.
PepGen Inc. reported that Chief Financial Officer Noel Donnelly received new equity awards. On March 1, 2026, he was granted a stock option for 300,000 shares at a price of $0.00 per share, classified as a grant or award acquisition. The option vests with 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, contingent on continued service.
On the same date, he also received 76,793 restricted stock units, each representing one share of common stock upon vesting. These RSUs vest in equal annual installments over four years starting March 1, 2027, subject to his continued service. Following these awards, his directly held common stock increased to 113,687 shares, which includes 11,938 shares acquired under the 2022 Employee Stock Purchase Plan on November 28, 2025.
PepGen Inc.’s President and CEO James G. McArthur received new equity awards. On March 1, 2026, he was granted a stock option for 731,250 shares of PepGen common stock at an exercise price of $0.0000 per share, all held directly.
He also received 187,688 restricted stock units, each representing one share of common stock upon vesting. These RSUs vest in four equal annual installments starting on March 1, 2027, while the stock option vests 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, all subject to his continued service.
PepGen Inc. reported a change to stock option grants held by its Executive Vice President and Head of R&D. On November 4, 2025, the board approved a repricing of this officer’s outstanding stock options granted under PepGen’s 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with the prior higher exercise prices, such as $9.83, remaining in place if conditions are not met.
The lower exercise price applies only if the officer satisfies a specified retention period; otherwise, the original exercise price will continue to apply. One of the options described vests 25% on the one-year anniversary of its grant date, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service or employment with the company at each vesting date.
PepGen Inc. reported a change to its President and CEO’s stock option grants. On November 4, 2025, the board approved a repricing of the executive’s outstanding stock options granted under the company’s 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, while all other terms of the options remain the same, except that the lower exercise price applies only if the executive satisfies a required retention period; otherwise, the original higher exercise prices will continue to apply.
The affected options, which are rights to buy PepGen common stock, generally vest over four years. For these grants, 25% of the shares vest on the first anniversary of the applicable vesting commencement or grant date, with the remaining shares vesting in 36 equal monthly installments, subject to continued service or employment on each vesting date.
PepGen Inc. disclosed that its Board of Directors approved a repricing of the Chief Financial Officer’s outstanding stock options on November 4, 2025. Several existing stock option grants with exercise prices of $10.88, $12, $15.25, and $16.62 were canceled and replaced with options at a new exercise price of $4.53, while keeping other terms the same. The reduced exercise price applies only if the CFO satisfies an applicable retention period; otherwise, the original higher exercise prices will continue to apply.
The affected options cover multiple grants under PepGen’s 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan, with expirations between November 10, 2031 and February 28, 2034. The filing notes that one grant vests over four years from an October 15, 2021 vesting start date, and others vest 25% after one year with the balance vesting in 36 equal monthly installments, all contingent on continued service.